News

  • 25 January 2021

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020. 

  • 11 January 2021

    Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the completion of a $75.0 million Series C private financing round.

  • 16 December 2020

    Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced today the launch of its “500K Club” to celebrate the company’s recently announced achievement of having more than 500,000 patients treated with the GentleWave Procedure. 

  • 8 December 2020

    Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced that more than 500,000 patients have been treated with the GentleWave Procedure. 

  • 3 December 2020

    Immunocore (or the “Company”), a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that it will present new clinical results on tebentafusp (IMCgp100) at the European Society of Medical Oncology Immuno-Oncology (ESMO IO) Virtual Congress on the 12th December. These data represent the primary clinical results from a Phase 2 study of tebentafusp in previously treated, metastatic uveal melanoma (mUM) patients.